Tuesday, September 1, 2026
← Back to archivePolicy
Policy•STAT News•Sep 1, 2026
Opinion: The Trump administration is burying science and health care in paperwork
background ▾
- •NIH grant awards have dropped dramatically with only 13% success rate and 25% less spending year-to-date, while scientists report spending >40% of time on administrative tasks rather than research due to new DEI screening and mid-grant revision requests
- •OMB proposed rule would insert political appointee review before peer review of all federal grants, fundamentally altering the scientific merit-based funding process (implementation delayed to at least Dec. 11 by Senate action)
- •Medicaid enrollment changes effective Jan. 1 include twice-yearly recertification, 80-hour/month community engagement requirements, and immigrant restrictions—expected to cause significant coverage loss despite technical eligibility of 92% of current recipients
Policy•STAT News•Sep 1, 2026
As MAHA champions nutrition, it’s ignoring the experts, dietitians say
background ▾
- •MAHA's nutrition agenda lacks alignment with dietitian workforce capacity; insurance coverage restrictions and low reimbursement have created a structural barrier to scaling nutrition interventions in healthcare.
- •New master's degree requirement (as of 2024) increases entry costs by ~$10,000-50,000 just as the field faces wage stagnation, threatening to further deplete the already-atrophying dietitian workforce.
- •Policy implications: Federal reimbursement reform (Medicare/Medicaid coverage expansion) and wage incentives will be necessary to operationalize MAHA's nutrition goals; watch for legislative action on dietitian coverage and professional reimbursement rates.
Policy•Endpoints News•Sep 1, 2026
ARCH Venture Partners targets $3 billion raise for latest fund
background ▾
- •ARCH Venture Partners targeting $3 billion for new fund—reflects continued VC confidence in biotech investment
ARCH Venture Partners
→ Read original articlePolicy•Endpoints News•Aug 31, 2026
Trump announces nine new MFN drug pricing deals
background ▾
- •Nine companies voluntarily agreeing to MFN pricing deals demonstrates the White House's leverage in driving industry pricing concessions outside formal CMS mechanisms
- •Companies appear motivated to avoid tariffs and mandatory inclusion in CMS pilot programs, suggesting these are credible competitive threats
- •Unclear which specific drugs and price points are involved, and whether these voluntary deals will establish precedent for broader mandatory negotiations
Policy•STAT News•Aug 31, 2026
New guidelines on migraine prevention reflect increasing options for patients
background ▾
- •First guideline update in 12 years formally endorses five CGRP-targeted preventive medications with high marks for efficacy and tolerability, potentially expanding patient eligibility and treatment uptake
- •Guidelines recommend preventive therapy for patients with ≥4 migraine days/month or functional impairment, but acknowledges many eligible patients remain undiagnosed or untreated
- •Complexity of stratified recommendations (by BMI, comorbidities, pregnancy status) may deter primary care adoption and implementation, creating potential access bottleneck despite expanded therapeutic options
Eli LillyAmgenAllerganatogepanteptinezumaberenumab
→ Read original articleMarket Access
Market Access•Endpoints News•Aug 31, 2026
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
background ▾
- •Eli Lilly is executing a highly active M&A strategy with 13 acquisitions already completed in 2026, signaling significant capital deployment toward immunology
- •The $2.875 billion valuation for Merida indicates Lilly's willingness to pay premium prices for immunology assets in a competitive landscape
- •Investors should monitor Lilly's cash position and debt levels given the pace and scale of acquisitions, as well as track which Merida programs advance clinically
Eli LillyMerida Biosciences
→ Read original articleMarket Access•Fierce Biotech•Aug 31, 2026
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
background ▾
- •Ipsoprubart is the first asset to receive both FDA breakthrough therapy and EMA PRIME designations for sHLH, with phase 1b data showing 100% OS at 8 weeks in 12 frontline malignancy-associated HLH patients
- •Phase 2/3 ipsoprubart enrollment expected to complete in 2027 with topline data shortly thereafter, positioning potential BLA filing in 2028
- •Monitor IPO pricing and investor reception as a gauge of market enthusiasm for rare immunoinflammatory indications; track phase 2/3 trial progress and any interim efficacy/safety readouts
Electra TherapeuticsSanofiNovartisipsoprubart (ELA026)ELA822
→ Read original articleMarket Access•Fierce Biotech•Aug 31, 2026
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
background ▾
- •Lilly acquires Merida's autoantibody-targeting platform for $2.875B, anchored by MER511 for Graves' disease with early phase 1 data showing robust reduction in thyroid-stimulating antibodies
- •The mechanism—selective degradation of pathogenic autoantibodies—offers disease modification potential versus symptomatic treatment, positioning Lilly to compete against emerging GD therapies from argenx, Immunovant (FcRn blockers), Sanofi (BTK inhibitor), and others
- •Watch for MER511 phase 1 completion and phase 2 initiation timelines; broader pipeline expansion potential in IgE-mediated allergies and membranous nephropathy; integration into Lilly's immunology portfolio and commercial strategy
Eli LillyMerida BiosciencesAmgenMER511MER769Tepezza
→ Read original articleMarket Access•Endpoints News•Aug 31, 2026
Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug
background ▾
- •Electra's IPO filing signals investor confidence in its Sanofi-partnered immunology platform and Phase 2/3-stage assets
- •Capital raise will accelerate clinical development of immunology programs, though specific drug candidates and their therapeutic areas are not detailed in the article excerpt
Electra TherapeuticsSanofi
→ Read original articleMarket Access•Fierce Biotech•Aug 31, 2026
Beyond the Bandwidth Ceiling: Redesigning Advanced Therapy Operating Models for the Digital Staff Era
background ▾
- •Advanced Therapy manufacturers are hitting an operational bandwidth ceiling because complexity scales non-linearly with patient volume—hiring cannot keep pace with the vein-to-vein orchestration demands of autologous and personalized therapies.
- •Enterprise software vendors are rebuilding platforms to enable AI agents ('digital staff') to interact directly with systems of record via APIs and command-line interfaces, decoupling human-screen interaction from backend data orchestration.
- •Monitor adoption of AI-augmented supply chain and commercial platforms in 2026–2027 for evidence that digital staff deployment can materially reduce operational friction in ATMP commercialization.
Deloitte Consulting LLPSalesforce
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 1, 2026
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
background ▾
- •GSK's mRNA flu vaccine candidate demonstrated superior immune responses versus standard and high-dose licensed comparators in phase 2, supporting advancement to phase 3 initiation this month
- •The dual-antigen design targeting both HA and NA represents a differentiated approach versus Moderna's approved mFlusiva (HA-only), potentially offering broader protection
- •Phase 3 success is critical for GSK to reverse recent 25% decline in flu vaccine revenues and capture share in a market where conventional vaccines show highly variable effectiveness (20-60%)
GlaxoSmithKlineModernaFLUm3HA.b-3NAmFlusiva
→ Read original articleClinical Trials•Fierce Biotech•Aug 31, 2026
‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
background ▾
- •Orzeyful (oveporexton) is the first FDA-approved orexin mimetic and addresses the root biology of narcolepsy type 1, a disorder previously managed only with stimulants like modafinil
- •Industry leaders compare orexin agonists to GLP-1 drugs in scope and market potential, with applications spanning fatigue, cognition, mood, and multiple sleep disorders beyond narcolepsy
- •Watch for Phase 2/3 trial data on off-label indications and competitive pipeline updates; multiple biotech firms are pursuing orexin agonists, making this a nascent but fast-moving therapeutic class
TakedaoveporextonOrzeyfulmodafinil
→ Read original articleClinical Trials•Fierce Biotech•Aug 31, 2026
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
background ▾
- •Three fatal IEC-HS events in Novartis' autoimmune CAR-T program spanning lupus nephritis, systemic sclerosis, vasculitis, and inflammatory myopathies forced a complete halt across multiple phase 1/2 and 2 studies
- •Parallel safety concerns at BMS with zola-cel suggest the toxicity signal may be platform-class related rather than compound-specific, potentially affecting the entire rapid manufacturing CAR-T approach in autoimmune disease
- •Oncology applications of both candidates remain unaffected, implying the safety risk is specific to autoimmune disease biology; watch for regulatory guidance on acceptable risk-benefit in this indication and whether rapid manufacturing platforms require protocol modifications
NovartisBristol Myers SquibbCabaletta Biorapcabtagene autoleucel (YTB323)zola-cel (BMS-986353)Breyanzi
→ Read original articleClinical Trials•Fierce Biotech•Aug 31, 2026
Natera teams with Angiex on cancer drug trial monitoring
background ▾
- •Natera's Signatera ctDNA test is being evaluated as an adjunctive biomarker for treatment response monitoring in a Phase 1 trial of a novel TM4SF1-targeted ADC, expanding its clinical validation beyond MRD detection
- •The collaboration reflects growing industry interest in liquid biopsy-guided treatment monitoring and may strengthen Signatera's clinical evidence profile for future commercial positioning
- •Monitor Phase 1 AGX101 readouts and whether Signatera data meaningfully differentiates treatment response assessment or predicts clinical outcomes relative to imaging alone
NateraAngiexSignateraAGX101
→ Read original articleClinical Trials•Fierce Biotech•Aug 31, 2026
ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial
background ▾
- •AZD5462 demonstrated early positive cardiac function improvements in both HFrEF (LVEF ≤35%) and HFmrEF (LVEF 41-55%) cohorts with acceptable safety profile, positioning it as a viable RXFP1 agonist candidate after competitors abandoned the class
- •The oral small-molecule formulation overcomes the tolerability and dosing challenges that plagued prior long-acting relaxin analogs, a critical hurdle for this mechanism
- •Watch for phase 3 Luminara outcomes trial initiation and efficacy/safety data; success here could establish a new relaxin-based therapeutic class for heart failure, but failure would further validate concerns about RXFP1 targeting in this indication
AstraZenecaEli LillyAZD5462AZD3427volenrelaxin
→ Read original article